Daily Antivirals Without an Outbreak: What the Evidence Says About Suppressive Therapy for Asymptomatic Herpes

For individuals diagnosed with herpes simplex virus — whether HSV-1 or HSV-2 — the period between outbreaks can feel deceptively calm. Skin appears normal. There is no discomfort, no visible lesion, and no obvious reason to take medication. And yet, beneath that surface calm, the virus may still be active in ways that carry meaningful consequences for both the individual and their partners.

This is the central tension at the heart of suppressive therapy: the question of whether to take daily antiviral medication when you feel entirely well. It is a question more patients are asking, and one that deserves a careful, evidence-based answer.

What Is Suppressive Therapy, and How Does It Differ From Episodic Treatment?

Antiviral treatment for herpes generally falls into two broad categories. Episodic therapy involves taking medication at the onset of an outbreak — typically for a short course of three to five days — to reduce the severity and duration of symptoms. Suppressive therapy, by contrast, involves taking a lower daily dose of an antiviral such as acyclovir on a continuous basis, regardless of whether symptoms are present.

The distinction matters because these two approaches serve different goals. Episodic treatment is primarily about managing acute symptoms. Suppressive therapy is about reducing the overall frequency of outbreaks, limiting asymptomatic viral shedding, and — critically — lowering the risk of transmitting the virus to a sexual partner.

The Asymptomatic Shedding Problem

One of the most clinically significant findings in herpes research over the past two decades concerns what virologists call asymptomatic shedding. This refers to the periodic reactivation of the herpes virus at or near the skin surface in the absence of any noticeable symptoms. The individual experiences nothing — no tingling, no lesion, no discomfort — yet the virus is present and potentially transmissible.

Studies published in peer-reviewed journals, including research conducted at the University of Washington, have demonstrated that asymptomatic shedding occurs in the majority of HSV-2 positive individuals, even those who report no recurrent outbreaks. In some studies, viral DNA was detected on the skin or mucosal surfaces on roughly 10 to 20 percent of days sampled among untreated individuals. For those taking daily suppressive therapy, that shedding rate was reduced by approximately 80 to 90 percent.

This is not a trivial finding. It suggests that the absence of symptoms does not equal the absence of transmission risk — and that suppressive therapy can meaningfully reduce that risk even when the patient feels entirely healthy.

What the Research Shows About Transmission Reduction

Perhaps the most cited evidence on this topic comes from a landmark randomized controlled trial published in the New England Journal of Medicine, which examined the effect of daily valacyclovir — a prodrug that converts to acyclovir in the body — on HSV-2 transmission within discordant couples (one partner positive, one negative). The trial found that daily suppressive therapy reduced the risk of transmission to an uninfected partner by approximately 48 percent overall, and by 75 percent when the outcome measured was symptomatic herpes in the newly infected partner.

While that trial used valacyclovir specifically, acyclovir operates through the same antiviral mechanism and has demonstrated comparable suppressive efficacy in clinical settings. Both medications inhibit viral DNA polymerase, preventing the virus from replicating efficiently.

For patients in relationships where one partner is herpes-positive and the other is not, these figures carry considerable weight. Suppressive therapy, combined with consistent condom use, represents the most evidence-supported approach to reducing transmission risk short of abstinence.

Who Is Suppressive Therapy Most Appropriate For?

Not every asymptomatic individual will have the same calculus. Several factors are worth considering when evaluating whether daily suppressive therapy makes sense for a particular patient.

Partnership status and sexual frequency. Individuals in ongoing sexual relationships — particularly those with herpes-negative partners — have the most direct reason to consider suppressive therapy. The transmission risk compounds over time with repeated sexual contact, making continuous antiviral coverage a rational protective strategy. Those who are not currently sexually active or who are in relationships where both partners are herpes-positive may weigh the benefit differently.

Outbreak frequency. Although suppressive therapy is relevant even for asymptomatic patients, individuals who experience six or more outbreaks per year are generally considered strong candidates for daily treatment by clinical guidelines issued by the CDC. Even those with fewer outbreaks may benefit if the psychological burden of anticipating recurrences is significant.

Psychological and quality-of-life considerations. Research consistently shows that herpes carries a disproportionate psychological burden relative to its medical severity for many patients. Studies have found that anxiety around potential transmission, uncertainty about asymptomatic shedding, and the social stigma associated with the diagnosis can materially affect quality of life. For some individuals, daily suppressive therapy provides not just clinical benefit but meaningful peace of mind — a factor that is legitimate and worth discussing with a healthcare provider.

Immunological status. Patients who are immunocompromised due to HIV, chemotherapy, organ transplantation, or other conditions face a higher risk of more frequent and severe herpes reactivations. In these populations, suppressive therapy is generally strongly recommended regardless of symptomatic status.

Safety and Long-Term Use

A common concern among patients considering daily suppressive therapy is whether long-term antiviral use is safe. The evidence here is reassuring. Acyclovir has been in clinical use for over four decades, and its long-term safety profile is well-established. Studies tracking patients on continuous suppressive therapy for periods of up to ten years have not identified significant safety signals related to organ toxicity or drug resistance in immunocompetent individuals.

That said, any long-term medication regimen should be reviewed periodically with a qualified healthcare provider. Kidney function monitoring may be appropriate for some patients, particularly those on higher doses or with pre-existing renal concerns.

The Episodic Alternative: When Is It Sufficient?

For individuals who are not sexually active, whose partners are also HSV-positive, or who experience only rare and mild outbreaks, episodic therapy remains a clinically appropriate and cost-effective strategy. Keeping a supply of antiviral medication on hand for prompt use at the first sign of prodromal symptoms — the tingling, itching, or localized sensitivity that often precedes an outbreak — can effectively limit the duration and severity of recurrences without the commitment of daily dosing.

The key limitation of episodic therapy is that it does not address asymptomatic shedding. For patients whose primary concern is transmission risk rather than personal symptom management, this is a meaningful gap.

Having the Conversation With a Provider

Ultimately, the decision between suppressive and episodic therapy is a clinical one that should be made in consultation with a licensed healthcare provider who can evaluate individual circumstances. For patients who feel that discussing this topic in person is uncomfortable or logistically difficult, telehealth and online pharmacy platforms have made it considerably more accessible to obtain a proper clinical evaluation and prescription without requiring an in-office visit.

At AcyclovirTabs, we recognize that navigating these decisions privately and efficiently matters to many of our patients. Whether you are newly diagnosed, reconsidering your current treatment approach, or simply seeking clearer information, understanding the evidence behind suppressive therapy is a meaningful first step toward making an informed choice about your health.